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Abstract
Background: MYG1 (Melanocyte proliferating gene 1, also C12orf10 in human) is a ubiquitous nucleo-mitochondrial
protein, involved in early developmental processes and in adult stress/illness conditions. We recently showed that
MYG1 mRNA expression is elevated in the skin of vitiligo patients. Our aim was to examine nine known
polymorphisms in the MYG1 gene, to investigate their functionality, and to study their association with vitiligo
susceptibility.
Methods: Nine single nucleotide polymorphisms (SNPs) in the MYG1 locus were investigated by SNPlex assay and/
or sequencing in vitiligo patients (n = 124) and controls (n = 325). MYG1 expression in skin biopsies was detected
by quantitative-real time PCR (Q-RT-PCR) and polymorphisms were further analysed using luciferase and YFP
reporters in the cell culture.
Results: Control subjects with -119G promoter allele (rs1465073) exhibited significantly higher MYG1 mRNA levels
than controls with -119C allele (P = 0.01). Higher activity of -119G promoter was confirmed by luciferase assay.
Single marker association analysis showed that the -119G allele was more frequent in vitiligo patients (47.1%)
compared to controls (39.3%, P < 0.05, OR 1.37, 95%CI 1.02-1.85). Analysis based on the stage of progression of the
vitiligo revealed that the increased frequency of -119G allele occurred prevalently in the group of patients with
active vitiligo (n = 86) compared to the control group (48.2% versus 39.3%, P < 0.05; OR 1.44, 95%CI 1.02-2.03).
Additionally, we showed that glutamine in the fourth position (in Arg4Gln polymorphism) completely eliminated
mitochondrial entrance of YFP-tagged Myg1 protein in cell culture. The analysis of available EST, cDNA and
genomic DNA sequences revealed that Myg1 4Gln allele is remarkably present in human populations but is never
detected in homozygous state according to the HapMap database.
Conclusions: Our study demonstrated that both MYG1 promoter polymorphism -119C/G and Arg4Gln
polymorphism in the mitochondrial signal of Myg1 have a functional impact on the regulation of the MYG1 gene
and promoter polymorphism (-119C/G) is related with suspectibility for actively progressing vitiligo.
Background
Vitiligo is an acquired pigmentary disorder characterized
by areas of depigmented skin resulting from loss of epi-
dermal melanocytes [1]. Considered the most common
pigmentary disorder, vitiligo occurs with a frequency of
0.1-2.0% in various populations [2]. Strong evidence
from twin and family studies indicates the importance
of genetic factors in the development of vitiligo [1]. Viti-
ligo involves complex interaction of environmental and
genetic factors that ultimately contribute to melanocyte
destruction, resulting in characteristic depigmented
lesions [3]. Recently we have proposed a novel gene,
MYG1 (Melanocyte proliferating gene 1)t ob ei n v o l v e d
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of MYG1 mRNA in both uninvolved and involved skin
in case of vitiligo [4]. Additionally we have shown that
Myg1 is ubiquitously expressed with subcellular localiza-
tion in the mitochondria and nucleus. MYG1 has differ-
ential pattern and level of expression during embryonic
development of mouse [5]; however, MYG1 expression
in normal adult tissues is stable and seems to be chan-
ged mainly as a response to stress/illness conditions
[4,6,7]. Recently, MYG1 has been found to be consis-
tently up-regulated also in skin biopsies from patients
with atopic eczema [8] that is a common inflammatory
skin disorder. Thus elevated MYG1 mRNA expression
has been described in two dermatological diseases.
The link between vitiligo and human 12q13 locus that
includes MYG1 has been recently reported. VDR gene
encoding vitamin D receptor in 12q13 locus associates
with vitiligo in a small inbred Romanian community [9].
However, the VDR and MYG1 genes are separated by
5.394 Mb and these two genes are not linked. The precise
function of Myg1 in the development of vitiligo is not
clear. However, up-regulation of several immune
response-related genes after siRNA-mediated knockdown
of MYG1 mRNA suggests that Myg1 may participate in
pathways proposed by autoimmune theory of vitiligo
pathogenesis [3]. Mitochondrial localization of Myg1 fits
also with alternative theory of altered mitochondrial
functionality of vitiligo patients [10,11].
In human, the MYG1 gene (also known as C12orf10) is
composed of seven exons that span 7.5 kb of genomic
DNA in chromosomal region 12q13. According to
NCBI’s dbSNP database http://www.ncbi.nlm.nih.gov/
SNP/ the MYG1 gene contains 10 polymorphisms that
are defined as single nucleotide polymorphisms (SNPs).
None of the MYG1 polymorphisms have been previously
studied in association analysis, but two polymorphisms
are potentially functional. SNP rs1465073 is located 119
bp upstream of MYG1 translation start site (ATG) and
we hereafter designate this SNP as MYG1 promoter poly-
morphism (-119C/G). Another polymorphism involves
nucleotides 11-12 (rs1534284-rs1534283) downstream
from translation start ATG. As it becomes evident from
EST and genomic DNA sequence analysis, these poly-
morphisms are not real SNPs because they always appear
as couple AA or GC (Table 1) in human populations.
These nucleotides are coding second and third position
of amino acid four in the N-terminus of Myg1 protein
(CAA and CGC, respectively). According to our previous
study, amino acid four is part of a mitochondrial target-
ing signal (MTS) of Myg1 protein and the polymorphism
is potentially functional, since it changes basic amino
acid into polar and uncharged. CGC that is common in
Caucasians codes for basic amino acid arginine (Arg);
CAA that according to the HapMap database http://
www.hapmap.org[12] is highly prevalent in the Nigerian
population is coding for polar and uncharged amino acid
glutamine (Gln). We hereafter refer to rs1534283-
rs1534284 polymorphism as Myg1 Arg4Gln.
The purpose of the present study was to examine nine
known SNPs in the MYG1 gene selected from the Hap-
Map database and to study their associations with viti-
ligo susceptibility. Moreover, we studied a possible
relationship between MYG1 promoter SNP (-119C/G)
and the amount of MYG1 mRNA being transcribed.
Finally our purpose was to characterize potentially func-
tional MYG1 polymorphisms further using cell culture
experiments.
Methods
Characteristics of study participants
Unrelated Caucasian patients living in Estonia with a
clear clinical diagnosis of vitiligo (n = 124, 88 female,
Table 1 Analysis of rs1534283 and rs1534284 variants (Myg1 Arg4Gln) in human EST (mRNA) and genomic DNA
sequences from NCBI and UCSC databases.
Fourth amino acid Database/Accession Sequence coding eight first
amino acids from MYG1 initial ATG
Source of mRNA
mRNA sequences Gln [GenBank:NM_021640] atgggacaccaattcctgcgcggc
Gln [GenBank:CR626228.1] atgggacaccaattcctgcgcggc fetal brain
Gln [GenBank:CR614390.1] atgggacaccaattcctgcgcggc neuroblastoma
Arg [GenBank:BC051871] atgggacaccgcttcctgcgcggc
Arg [GenBank:BC013956] ccgcttcctgcgcggc
Arg [GenBank:AF289485] atgggacaccgcttcctgcgcggc melanocytes
Genomic DNA Gln [GenBank:NT_029419] ATGGGACACCAATTCCTGCGCGGC
Gln [GenBank:NC_000012] ATGGGACACCAATTCCTGCGCGGC
Gln UCSC database ATGGGACACCAATTCCTGCGCGGC
Arg [GenBank:NW_925395.1] ATGGGACACCGCTTCCTGCGCGGC
First (ATG) and fourth (CAA or CGC) amino acids are underlined.
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Page 2 of 936 male, age range 18-82 years, mean age of onset of
vitiligo 27.8 years) were enrolled at the Department of
Dermatology, University of Tartu, Estonia. The diagnosis
of vitiligo was based on such clinical signs as character-
istic skin depigmentation with typical localization and
white colour on the skin lesions under Woods lamp.
The clinical types of vitiligo were classified as focal (one
or few macules in a nondermatomal distribution; n = 5),
segmental (unilateral segmental distribution; n = 4),
acrofacial (distal extremities and face; n = 11), vulgaris
(scattered over the body; n = 101) or universal (over
90% depigmentation; n = 3). Based on the stage of pro-
gression of the disorder, patients were divided into two
subgroups: patients with active vitiligo (in which new
lesions appeared and existing lesions increased in size
over the past 3 months; n = 86) and patients with stable
vitiligo (in which depigmentation did not increase dur-
ing the last 3 months; n = 38). Patients were also
divided into four subgroups based on the extent of
the skin lesion: less than 10% (n = 65); 10-50% (n = 37);
51-90% (n = 15) and more than 90% (n = 3). 46 patients
( 3 7 . 1 % )h a do n eo rm o r ed i s e a s eo fa u t o i m m u n eo r i g i n
including autoimmune thyreoiditis, rheumatoid arthritis
and diabetes, psoriasis, alopecia areata and pernicious
anemia. The control group consisted of 325 healthy
unrelated Caucasians (180 female, 145 male, age range
18-71 years) without a personal or family history of viti-
ligo as described earlier [4]. The Ethics Review Commit-
tee on Human Research of the University of Tartu
approved the study and written informed consent was
obtained from all participants.
Detection and statistical analysis of the human MYG1
gene polymorphisms
DNA was extracted from blood samples by standard
salting-out method. A panel of nine SNPs located inside
and also up- and downstream of the MYG1 gene was
investigated. The ID numbers from NCBI’s dbSNP data-
base of MYG1 SNPs that were examined in this study
are listed on Figure 1. For the SNPs rs2694861,
rs1465073, rs1534284, rs4759054, rs4325348, rs2279025,
rs1545650, and 4759281 the Applied Biosystems (Foster
City, California) SNPlex assay pool was used. The Zip-
Code probes were detected with an Applied Biosystems
3730 DNA Analyzer, and data interpretation was per-
formed with the Applied Biosystems Genemapper v4.0
software [13]. SNPbrowser version 3.5 was used for SNP
selection and SNPlex assay pool design. Single marker
association analysis was performed using the Haploview
program [14]. Allele frequencies were investigated using
the chi-square test. To evaluate deviation from the
Hardy-Weinberg equilibrium, observed and expected
genotype frequencies were compared by Fisher’se x a c t
test in the examined groups (cases and controls).
Pairwise linkage disequilibrium (LD) between markers
was estimated by a log-linear model and standardized D’
characteristics were used to demonstrate the extent of
disequilibrium. Since SNPlex assay was not functional
for detecting rs1534284, we used direct sequencing for
rs153484 and neighbour SNP rs1534283 in 54 subjects
(24 vitiligo patients and 30 healthy controls) using ABI
Genetic Analyzer 310 (Applied Biosystems, Foster City,
CA, USA). The direct sequencing of incidental DNA
samples was also performed for rs1465073 for verifica-
tion of the SNPlex results.
Detection of MYG1 mRNA levels by real-time PCR
Expression of MYG1 mRNA in the skin biopsies
of human subjects was measured as described previously
and partially samples from our previous study were used
[4].
Gene expression level of MYG1 was detected applying
TaqMan Assay-On-Demand (Hs000222208_m1, FAM-
labelled MGB-probe) gene expression assay mix (20×,
Applied Biosystems, Foster City, CA, USA) and Taq-
Man® Universal PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) in the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Reactions were carried out in 10 μl
reaction volumes in four replicates. Data is presented as
Figure 1 Genomic localization of single nucleotide
polymorphisms (SNPs) in the MYG1 gene that were examined
in this study. Relative positions of selected SNPs are represented
by their ID number from NCBI’s dbSNP database. Grey boxes are
representing exons and arrow indicates the direction of
transcription of MYG1 gene.
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-ΔCT calculated in relation to the HPRT-1 [15] and
statistical analysis was performed by using t-test. For
analysis of functional significance of promoter genotype
in the regulation of gene expression, we used subjects
(n = 52) from whom both genomic DNA and skin
biopsy was available. MYG1 expression was measured
from skin biopsy of 24 normal control subjects
(15 female, 9 male) and 28 vitiligo patients (20 female,
8 male).
MYG1 cDNA constructs
Full-length human MYG1 cDNA with both variants for
Myg1 Arg4Gln polymorphism were inserted into
pEYFP-N1 vector (Clontech, Palo Alto, USA) by using
NheI and SacII restriction sites. Myg1 4Arg cDNA was
cloned by using primers 1 and 3 (see Table 2 for primer
sequences) and Myg1 4Gln cDNA with primers 2 and 3.
For MYG1 promoter analysis, fragments from MYG1
promoter area were cloned into pGL3-Basic Vector
(Promega) by using KpnI and HindIII restriction sites.
Genomic DNA from two control subjects was used to
make reporter gene constructs and all fragments were
sequenced to verify genotype and lack of additional
mutations in the constructs. Short promoter fragment
that includes 291 bp genomic sequence before MYG1
coding ATG was amplified by using primers 4 and 6;
long, 1 kb promoter fragment was amplified with pri-
mers 5 and 6. Both long and short promoter fragments
were created in two variants with respect of MYG1 pro-
moter polymorphism -119C/G. Two different lengths of
promoter fragments were used because of lack of infor-
mation how long promoter area is needed to trigger
maximum promoter activity for the MYG1 gene. 291 bp
fragment was used, because it is the maximum MYG1
unique promoter area that is not overlapped with 3’-
UTR of PFDN5.
Cell culture experiments and luciferase assay
All cell culture experiments were performed with HeLa
cells. MYG1 cDNA and promoter DNA constructs were
transfected into cells by FuGENE 6 Transfection
Reagent (Roche, USA). Mitochondria were visualized by
using MitoTracker Red CMXRos (Molecular Probes,
USA). Images were acquired with a Zeiss LSM 510 con-
focal laser-scanning microscope. For luciferase assay
200,000 cells per well were plated into six-well cell-cul-
ture dishes 24 h prior transfections and five replicas
were created for each plasmid, with two different DNA
preparations of the same clone. For each well 1 μgo f
the construct was transfected along with 1 μgo fp R L O
renilla luciferase reporter vector as the control for trans-
fection efficiency. Luciferase gene with CMV promoter
was used as positive control and empty pGL3-Basic vec-
tor as negative control. The cells were harvested 24 h
after transfection, and the activity of firefly and renilla
luciferase was measured with GloMax 96 Luminometer
(Promega). The normalized luciferase data (renilla/fire-
fly) were used to perform statistics (t-test) and are
expressed relative to empty pGL3-Basic vector.
Results
MYG1 gene polymorphisms associated with vitiligo
susceptibility
From the initial nine SNPs, we failed to genotype
rs1534284 and rs4759054 with SNPlex platform. More-
over, four SNPs (rs2694861, rs4325348, rs2279025, and
4759281) were monogenic in Estonian population with
only major alleles being present. Sequencing genomic
DNA of 54 subjects (30 controls and 24 vitiligo patients)
revealed that rs1534284/rs1534283 double-polymorph-
ism is likewise prevalently monogenic in Estonian popu-
lation with only Myg1 4Arg allele being present. The
polymorphic SNPs in our study were rs1465073 in
MYG1 promoter (-119C/G) and rs1545650 (C/T)
located in short 281 bp intergenic area between MYG1
and AAAS [GenBank:NM_015665] gene. Direct sequen-
cing of rs1465073 polymorphism in 40 incidental sub-
jects completely overlapped with SNPlex results. The
minor allele (G) of the rs1465073 was more frequent in
the vitiligo group compared to the control group (47.1%
versus 39.3%, P = 0.0385; OR 1.37, 95%CI 1.02-1.85)
consistent with a susceptibility effect. Analysis based on
the stage of progression of the vitiligo revealed that the
increased frequency of the minor allele (G) of rs1465073
occurred prevalently in the group of patients with active
vitiligo (n = 86) compared to the control group (48.2%
Table 2 Primer sequences used for cloning DNA constructs.
No Name Sequence
1. Human MYG1 4Arg ATG Fw 5’-ATATgctagcCATGGGACACCGCTTCCTGCGCG-3’
2. Human MYG1 4Gln ATG Fw 5’-ATATgctagcCATGGGACACCAATTCCTGCGCG-3’
3. Human MYG1 noSTOP Rev 5’-ATATccgcggAGATTTGTGGGAGGTATGAG-3’
4. MYG1-300KpnIF 5’-TATAggtaccAGAATGTTGGTCTTTTCTTGGATTAAGC-3’
5. MYG1-1kbKpnIF 5’-TATAggtaccGAGAAGAGTCTCATTCTCACC-3’
6. MYG15utrHindIIIR 5’-ATATaagcttAAGCAGCTCCCTGCAGGGAG-3’
First (ATG) and fourth (CAA or CGC) amino acids in primers 1 and 2 are underlined; restriction sites are given in lowercase letters.
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There was no statistically significant effect in the distri-
bution of the minor allele of rs1465073 between patients
with stable vitiligo (n = 38) and control group (44.6%
versus 39.3%, P = 0.378; OR 1.24, 95%CI 0.76-2.02). The
average age, mean onset and duration of vitiligo did not
differ between patients with active versus stable vitiligo.
Although minor allele (T) of rs1545650 was more preva-
lent in patients than in control individuals (3.3% versus
1.6%, respectively), the difference remained not signifi-
cant (P = 0.172; OR 2.08; 95% CI 0.71-6.07). LD analysis
(solid spine algorithm) indicated that the rs1465073
polymorphism, which is located in the promoter of the
MYG1 gene, was not in strong LD with the MYG1
rs1545650 polymorphism located 7.7 kb downstream (|
D’| 0.23). No significant effects in the distribution of the
MYG1 gene allele frequencies were found when patients
with different clinical subtypes of vitiligo were analysed
separately or when analysis was performed regarding the
extent of the skin lesion. Also, polymorphisms in the
MYG1 gene were not related with concurrent autoim-
mune disease in vitiligo patients.
In vivo and in vitro studies of MYG1 promoter activity
MYG1 mRNA levels in the skin of healthy controls cor-
related with -119C/G polymorphism (Figure 2A, healthy
controls). MYG1 mRNA expression of G homozygous
subjects (2
-ΔCT = 3.87 ± 0.67) was significantly (P =
0.0107) higher than in subjects who had homozygous C
in the same position (2
-ΔCT =2 . 6 4±0 . 3 9 ) .T h ee x p r e s -
sion value of heterozygous subjects remained in between
(2
-ΔCT = 3.43 ± 1.29), but due to relatively high devia-
tion, it was not statistically different from either
homozygous groups. In vitiligo patients we could not
detect a similar difference and there were no statistically
significant differences in MYG1 mRNA levels between
the groups divided according to -119C/G genotypes
(Figure 2A, vitiligo patients). Additionally we performed
luciferase reporter assay in the cell culture to measure
the influence of -119C/G polymorphism in the in vitro
system with minimum interacting factors. In luciferase
assay both short and long promoter fragment with
-119G allele had more than 2.5 fold higher activity than
-119C allele (Figure 2B). Comparison of 291 bp promo-
ter fragments showed that -119G allele had 2.66 times
higher activity (P < 0.01) and comparison of 1 kb pro-
moter fragments revealed that -119G allele had 2.89
times higher activity (P < 0.01). Additionally our results
demonstrate that 291 bp MYG1 promoter fragment is
sufficient to trigger maximum activity of the MYG1
g e n e .T h eC M Vp r o m o t e rt h a tw eu s e da sap o s i t i v e
control induces high-level constitutive expression in a
variety of mammalian cell lines [16]. In general MYG1
promoter was 4-8 times less active than CMV promoter
depending on the promoter allele (data not shown).
Arg4Gln polymorphism affects subcellular localization of
Myg1 in cell culture
To study if Myg1 Arg4Gln polymorphism has an influ-
ence on subcellular localization of Myg1, we expressed
both YFP-tagged cDNA variants for Myg1 Arg4Gln
polymorphism in HeLa cells. We have previously shown
that full-length Myg1 4Arg cDNA that is common
among Caucasians localizes into the nucleus and mito-
chondria [5]. The same localization was confirmed in
the current study (Figure 3A). Myg1 4Gln variant was
Figure 2 Impact of MYG1 promoter SNP (-119C/G) on MYG1 mRNA expression.( A )MYG1 mRNA expression levels in the skin biopsies of
healthy subjects and vitiligo patients; n indicates number of subjects in each group; the error bars present standard deviation of the mean.
Abbreviations: HS - healthy skin; LS - lesioned skin. (B) MYG1 promoter activity in luciferase assay. Data is shown relative to the activity of empty
pGL3-Basic. Pattern codes corresponding to three genotypes for both (A) and (B) are shown on the right. * P < 0.05; ** P < 0.01
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detect YFP signal in the nucleus and slight homogenous
signal in the cytoplasm, but there were no cells where
Myg1 4Gln-YFP signal would be overlapped with Mito-
Tracker (Figure 3B).
Discussion
MYG1 mRNA expression is elevated in the skin of viti-
ligo patients [4]. In the present study we showed that
MYG1 mRNA levels in skin samples of healthy controls
correlate with MYG1 promoter polymorphism -119C/G
and subjects with homozygous -119G allele have signifi-
cantly higher MYG1 mRNA levels than subjects with
homozygous -119C allele. Higher activity of -119G pro-
moter was confirmed by using in vitro luciferase repor-
ter assay. -119G promoter was on average more than
2.5 fold more active regardless of the length of the pro-
moter fragment. Single marker association analysis
showed that the active -119G allele was more frequent
in vitiligo patients compared to controls. Further
analysis based on the stage of progression of the vitiligo
revealed that the increased frequency of more active
-119G allele occurred prevalently in the group of
patients with active vitiligo compared to the control
group. This finding is in line with our previous study [4]
w h e r en od i f f e r e n c ei nMYG1 expression between non-
lesional skin of stable subtype of vitiligo and healthy
control subjects was detected. At the same time a statis-
tically significant increase in MYG1 expression in both
lesional and nonlesional skin of patients with active viti-
ligo and in lesional skin of patients with stable vitiligo
was found, raising the possibility that MYG1 is least
reactive in the stable stage unaffected vitiligo skin [4].
According to growing evidence, the MYG1 gene is pre-
dominantly implicated in actively progressing vitiligo.
Minor allele -119G was related to higher MYG1
mRNA levels only in control group, but not in vitiligo
group. In general, MYG1 mRNA is elevated in both
involved and uninvolved skin of vitiligo patients despite
active or less active promoter genotype. This finding
suggests that increased MYG1 mRNA level in the skin
of vitiligo patients is only partially dependent on endo-
genous promoter activity and there are other factors
besides -119C/G polymorphism that mediate MYG1
expression levels in the skin of vitiligo patients. It is
likely that part of the effect of increased MYG1 expres-
sion in vitiligo comes from higher prevalence of natu-
rally more active -119G promoter carriers in vitiligo
group. We propose that the elevation of MYG1 expres-
sion in vitiligo can be both cause and effect depending
on the case. Vitiligo patients with -119G promoter have
genetic inclination for higher expression and patients
with less active promoter genotype harbour other
genetic susceptibility loci, but MYG1 expression in their
skin is still increased as a consequence of cellular
changes that characterize vitiligo skin. Alteration of
p300 (E1A-associated 300 kDa protein) binding site is a
potential reason why MYG1 -119G promoter allele is
more active in normal control subjects and in vitro luci-
ferase assay. The analysis of binding sites in the -119
promoter region was performed by using TRANSFAC
software (Figure 4A and 4B). Consensus DNA binding
sequence for p300 is 5’-GGGAGTG-3’ [17] that corre-
sponds 100% to the bases from -125 to -119 of MYG1-
119G allele. MYG1-119C alters the last position of the
binding site for p300 (5’-GGGAGTC-3’). p300 that is
mostly known as histone deacetylase can also act as a
bridge or scaffold between transcription factors and the
basal transcription machinery to enhance the transcrip-
tion activation [18]. However, besides p300 there can be
other transcriptional or epigenetic factors that are sensi-
tive to MYG1-119C/G substitution.
Expression of YFP-tagged Myg1 fusion proteins in
HeLa cells revealed that glutamine in fourth position
Figure 3 Subcellular localization of full-length human MYG1
cDNA with both variants for Myg1 Arg4Gln polymorphism.
Mitochondrial localization YFP tagged MYG1 cDNA with arginine in
the position amino acid four (A) is completely eliminated if arginine
is replaced with glutamine (B). Scale bars represent 10 μm.
Philips et al. BMC Medical Genetics 2010, 11:56
http://www.biomedcentral.com/1471-2350/11/56
Page 6 of 9(Myg1 4Gln allele) completely eliminated mitochondrial
entrance of YFP-tagged Myg1 protein. Our analysis of
human ESTs and genomic sequences in NCBI and
UCSC http://genome.ucsc.edu/ databases confirm that
Myg1 Arg4Gln polymorphism is present in human
populations (Table 1). According to currently available
data, there can be either arginine or glutamine in the
fourth position of Myg1 in humans and here we showed
that only positively charged arginine in the fourth posi-
tion enables mitochondrial entrance. It is likely that
acidic glutamine disturbs a common property of mito-
chondrial targeting sequence to form an amphiphilic
helical structure that is essential for the effective trans-
port of a mitochondrial protein [19]. It has been
described earlier that single amino acid substitution can
completely eliminate the functionality of MTS: single
substitution glycine 12 to glutamic acid in a mitochon-
drial targeting sequence disturbs mitochondrial localiza-
t i o no ft h eh u m a nw i l d - t y p e8 - o x o g u a n i n eD N A
glycosylase (hOGG1) [20]. Our results provide another
example of a single amino acid substitution in mito-
chondrial signal that eliminates mitochondrial entrance
of a protein.
Finally, we sequenced 54 Caucasian subjects for Myg1
Arg4Gln and confirmed that they were all homozygous
for Myg1 4Arg allele that corresponds to previous Hap-
Map data for 60 Caucasian subjects (Utah residents with
ancestry from Northern and Western Europe). Accord-
ing to HapMap database heterozygosity for Myg1
Arg4Gln polymorphism (rs1534284) has been currently
detected only in YRI (Yoruba in Ibadan) population
from Nigeria. Among 57 subjects from YRI population
who were genotyped for HapMap project 20 subjects
(35.1%) were heterozygous for Myg1 Arg4Gln poly-
morphism but there are no subjects who are homozy-
gous for Myg1 4Gln allele. According to currently
available data, Myg1 4Gln allele that disturbs mitochon-
drial entrance of Myg1 has never been detected in the
homozygous state. We propose that persons with Myg1
4Gln variant do not survive or have a health condition
that keeps them out from the study groups. High fre-
quency of general heterozygosity (0.175) of Myg1
Arg4Gln can also be a target of natural selection, simi-
larly with 9-amino acid deletion in SLC4A1 gene that is
completely lethal in the homozygous state [21], but het-
erozygosity persists with a maximum frequency of 0.175
due to a protective effect with respect to cerebral
malaria in Southeast Asia. The frequency of heterozyg-
osity (Myg1 Arg4Gln) in Nigeria is similar to 9-amino
a c i dd e l e t i o ni nt h eS L C 4 A 1g e n ei nA s i a( 0 . 1 7 5 ) .
Therefore it is likely that Myg1 Arg4Gln is a target of
similar selection. Considering our present subjects, we
cannot explain the relevance of our finding in vitiligo,
but we propose that Myg1 has crucial functions inside
mitochondria that may be implicated in vitiligo.
The expression pattern of Myg1 is ubiquitous, but
there is evidence that Myg1 function in the skin can be
differential, for example, during embryonic development,
Myg1 is predominantly expressed in the ectoderm
derived tissues, including epidermis [5], indicating that
Myg1 is involved in the development of skin, therefore
Myg1 function in the skin can be specific at least in some
phases of development. Our association analysis and
expression studies suggest that MYG1 is one of the genes
Figure 4 Analysis of binding sites in the -119 promoter region using TRANSFAC software. (A) Sequence of -119G promoter allele. (B)
Sequence of -119G promoter allele. Arrowhead points to a single nucleotide polymorphism, G in (A) and C in (B).
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factors is responsible for the development of vitiligo.
However, MYG1 expression in the skin seems to be not
specific to melanocytes: according to our preliminary
results, MYG1 expression in cultured melanocytes is
lower than expression in full skin biopsy and comparable
or equal with MYG1 expression in cultured fibroblasts
derived from the same skin (data not shown). Therefore
the precise function of MYG1 in the development of viti-
ligo is still unclear but we have two major hypotheses:
up-regulation of several immune system-related genes
after MYG1 siRNA knockdown in cell culture [5] sug-
gests that Myg1 can act as a mediator in the immune
processes that are disturbed in vitiligo patients. Several
theories have been proposed about the mechanism of
vitiligo pathogenesis but autoimmune hypothesis is the
most popular at present [22] and a recent comprehensive
review about vitiligo genetics [3] emphasizes that genetic
factors underlying autoimmune diseases and vitiligo are
often overlapping. Besides immunological approach, the
study of the metabolic deregulations leading to toxic
damage of the melanocytes appears to be more and more
relevant [23]. Therefore, alternatively: mitochondrially
localized Myg1 can be involved in the regulation of
altered metabolism and imbalance of antioxidants in viti-
ligo. Growing amount of data provides further evidence
for an altered mitochondrial functionality of vitiligo
patients [10,11]. Different authors suggest that oxidative
stress plays a central role in the process of melanocyte
degradation [10,23-25]. The fact that MYG1 expression is
elevated in both uninvolved and involved skin in case of
vitiligo is in line with findings that melanocytes from nor-
mally pigmented skin of vitiligo patients also exhibit high
susceptibility to chemical and physical oxidative stress
[23]. Further studies will be needed to explain the
mechanisms of vitiligo pathogenesis and to understand
the precise function of Myg1 in vitiligo.
Conclusions
Our in vivo and in vitro promoter activity analysis
together with association analysis confirmes that -119C/
G polymorphism influences MYG1 mRNA levels. Our
results suggest that more active -119G is the risk-allele
for the development of vitiligo and more specifically
risk-allele for the maintenance of the active progression
stage of the disease. We also showed that Myg1 4Gln
allele that exists only in heterozygous state in humans
disturbs mitochondrial entrance of Myg1. Because our
subjects were consistently homozygous for Myg1 4Arg
allele, we cannot confirm the relevance of Myg1
Arg4Gln in vitiligo, but our results suggest that Myg1
has indispensable functions in the mitochondria and
might be implicated in mitochondrial damage often
present in vitiligo patients. Taken together, our study
demonstrated that both MYG1 promoter polymorphism
-119C/G and Arg4Gln polymorphism in the mitochon-
drial signal of Myg1 have a functional impact on the
regulation of the MYG1 gene.
Acknowledgements
The present study was financed by University of Tartu research grant PARFS
07915, Estonian Ministry of Education grants No. SF0180148s08 and
SF0180043s07, Estonian Science Foundation Grants 6576 and 7479, the
European Union through the European Regional Development Fund and by
the Archimedes Foundation.
Author details
1Department of Physiology, University of Tartu, 19 Ravila Street, Tartu 50411,
Estonia.
2Department of Dermatology and Venerology, University of Tartu, 31
Raja Street, 50417 Tartu, Estonia.
3Department of Paediatric Surgery, Tallinn
Children’s Hospital, 28 Tervise Street, 13419 Tallinn, Estonia.
4Department of
Clinical Biochemistry, Rigshospitalet, University of Copenhagen, DK-2100
Copenhagen, Denmark.
Authors’ contributions
MAP designed and performed cell culture experiments, designed and
prepared DNA plasmids, interpreted the results and wrote the draft of the
manuscript. KK performed statistical analysis and participated in drafting the
manuscript. KK and MK confirmed the diagnosis of vitiligo patients and
coordinated the collection of blood and skin samples of the study
participants. KK and SK designed SNPlex assay pool. KK, RR and ER prepared
DNA samples for genotyping and participated in genotyping studies. EA and
PR performed the Q-RT-PCR analysis. PR, OP and JV participated in cell
culture experiments and JV made confocal microscopy images. FCN, EV, HS,
SK conceived the study, participated in its coordination and draft revision.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 December 2009 Accepted: 8 April 2010
Published: 8 April 2010
References
1. Zhang XJ, Chen JJ, Liu JB: The genetic concept of vitiligo. J Dermatol Sci
2005, 39:137-146.
2. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA: Epidemiology of
vitiligo and associated autoimmune diseases in Caucasian probands and
their families. Pigment Cell Res 2003, 16:208-214.
3. Spritz RA: The genetics of generalized vitiligo and associated
autoimmune diseases. Pigment Cell Res 2007, 20:271-278.
4. Kingo K, Philips MA, Aunin E, Luuk H, Karelson M, Rätsep R, Silm H, Vasar E,
Kõks S: MYG1, novel melanocyte related gene, has elevated expression
in vitiligo. J Dermatol Sci 2006, 44:119-122.
5. Philips MA, Vikesaa J, Luuk H, Jonson L, Lilleväli K, Rehfeld JF, Vasar E,
Kõks S, Nielsen FC: Characterization of MYG1 gene and protein:
subcellular distribution and function. Biol Cell 2009, 101:361-373.
6. Hawse JR, Hejtmancik JF, Huang Q, Sheets NL, Hosack DA, Lempicki R,
Horwitz J, Kantorow M: Identification and functional clustering of global
gene expression differences between human age-related cataract and
clear lenses. Mol Vis 2003, 9:515-537.
7. Kõks S, Luuk H, Nelovkov A, Areda T, Vasar E: A screen for genes induced
in the amygdaloid area during cat odor exposure. Genes Brain Behav
2004, 3:80-89.
8. Sääf AM, Tengvall-Linder M, Chang HY, Adler AS, Wahlgren CF, Scheynius A,
Nordenskjöld M, Bradley M: Global Expression Profiling in Atopic Eczema
Reveals Reciprocal Expression of Inflammatory and Lipid Genes. PloS One
2008, 3:e4017.
9. Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S,
Costin G, Das P: Autoimmune Diseases and Vitamin D Receptor Apa-I
Philips et al. BMC Medical Genetics 2010, 11:56
http://www.biomedcentral.com/1471-2350/11/56
Page 8 of 9Polymorphism are Associated with Vitiligo in a Small Inbred Romanian
Community. Acta Derm Venereol 2006, 86:209-214.
10. Dell’Anna ML, Urbanelli S, Mastrofrancesco A, Camera E, Iacovelli P,
Leone G, Manini P, D’Ischia M, Picardo M: Alterations of mitochondria in
peripheral blood mononulcear cells of vitiligo patients. Pigment Cell Res
2003, 16:553-559.
11. Prignano F, Pescitelli L, Becatti M, Di Gennaro P, Fiorillo C, Taddei N, Lotti T:
Ultrastructural and functional alterations of mitochondria in perilesional
vitiligo skin. J Dermatol Sci 2009, 54:157-167.
12. The International HapMap Consortium: The International HapMap Project.
Nature 2003, 426:789-796.
13. De La Vega FM, Gordon D, Su X, Scafe C, Isaac H, Gilbert DA, Spier EG:
Power and sample size calculations for genetic case/control studies
using gene-centric SNP maps: application to human chromosomes 6, 21,
and 22 in three populations. Hum Hered 2005, 60:43-60.
14. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263-265.
15. Kingo K, Aunin E, Karelson M, Rätsep R, Silm H, Vasar E, Kõks S: Expressional
changes in the intracellular melanogenesis pathways and their possible
role the pathogenesis of vitiligo. J Dermatol Sci 2008, 52:39-46.
16. Fitzsimons HL, Bland RJ, During MJ: Promoters and regulatory elements
that improve adeno-associated virus transgene expression in the brain.
Methods 2002, 28:227-236.
17. Rikitake Y, Moran E: DNA-binding properties of the E1A-associated 300-
kilodalton protein. Mol Cell Biol 1992, 12:2826-2836.
18. Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional
bridges and scaffolds. J Cell Sci 2001, 114:2363-2373.
19. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y,
Shimizu Y, Mizuno Y: Structural Dimorphism in the Mitochondrial
Targeting Sequence in the Human Manganese Superoxide Dismutase
Gene A Predictive Evidence for Conformational Change to Influence
Mitochondrial Transport and a Study of Allelic Association in Parkinson’s
Disease. Biochem Biophys Res Commun 1996, 226:561-565.
20. Audebert M, Charbonnier JB, Boiteux S, Radicella JP: Mitochondrial
targeting of human 8-oxoguanine DNA glycosylase hOGG1 is impaired
by a somatic mutation found in kidney cancer. DNA Repair 2002,
1:497-505.
21. Wilder JA, Stone JA, Preston EG, Finn LE, Ratcliffe HL, Sudoyo H: Molecular
population genetics of SLC4A1 and Southeast Asian Ovalocytosis. J Hum
Genet 2009, 54:182-187.
22. Westerhof W, d’Ischia M: Vitiligo puzzle: the pieces fall in place. Pigment
Cell Res 2007, 20:345-359.
23. Dell’Anna ML, Picardo MA: Review and a new hypothesis for non-
immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res
2006, 19:406-411.
24. Maresca V, Roccella M, Roccella F, Camera E, Del Porto G, Passi S,
Grammatico P, Picardo M: Increased sensitivity to peroxidative agents as
possible pathogenic factor of melanocyte damage in vitiligo. J Invest
Dermatol 1997, 109:310-213.
25. Jimbow K, Chen H, Park JS, Thomas PD: Increased sensitivity of
melanocytes to oxidative stress and abnormal expression of tyrosinase-
related protein in vitiligo. Brit J Dermatol 2001, 144:55-65.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/56/prepub
doi:10.1186/1471-2350-11-56
Cite this article as: Philips et al.: Promoter polymorphism -119C/G in
MYG1 (C12orf10) gene is related to vitiligo susceptibility and Arg4Gln
affects mitochondrial entrance of Myg1. BMC Medical Genetics 2010
11:56.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Philips et al. BMC Medical Genetics 2010, 11:56
http://www.biomedcentral.com/1471-2350/11/56
Page 9 of 9